Zacks Investment Research upgraded shares of Clinigen Group Plc (NASDAQ:CLIGF) from a hold rating to a buy rating in a research report released on Tuesday. The brokerage currently has $15.00 target price on the stock.

According to Zacks, “Clinigen Group plc is a pharmaceutical and services company. Its business focuses in areas of global medicine supply; clinical trial, unlicensed and licensed medicines. Clinigen Group plc is headquartered in Burton-on-Trent, the United Kingdom. “

Clinigen Group Plc (CLIGF) opened at 13.90 on Tuesday. Clinigen Group Plc has a one year low of $8.70 and a one year high of $13.90. The firm has a market capitalization of $1.60 billion and a price-to-earnings ratio of 86.34.

COPYRIGHT VIOLATION WARNING: This article was first reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this article on another domain, it was illegally copied and reposted in violation of U.S. & international copyright & trademark law. The legal version of this article can be viewed at https://www.thecerbatgem.com/2017/09/13/clinigen-group-plc-cligf-upgraded-by-zacks-investment-research-to-buy.html.

Receive News & Stock Ratings for Clinigen Group Plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clinigen Group Plc and related stocks with our FREE daily email newsletter.